BioProgress plc: Change in nominated adviser

16 April 2007

London, UK. BioProgress plc (the 'Company') (AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, is pleased to announce that it has appointed Nomura Code Securities Limited (‘Nomura Code’) as its Broker and Nominated Adviser with immediate effect. Nomura Code has been appointed because of its strength in the life sciences sector which the Company believes will be beneficial as its business develops.

For further information:

BioProgress Plc	+ 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO
Buchanan Communications	+44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court
Nomura Code Securities Limited	+44 (0) 20 7776 1200
Richard Potts

About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™ polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com